By the Numbers
By the Numbers
June 20, 2020
2 min read
Save

7 recent reports on inflammatory bowel disease

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Healio Gastroenterology presents the following reports on the most recent research on inflammatory bowel disease.

These reports include new research on the impact of food insecurity, frailty and a potential therapy for ulcerative colitis.

Food insecurity, lack of social support common in IBD

One in eight patients with inflammatory bowel disease are food insecure and lack social support, according to research published in Clinical Gastroenterology and Hepatology.

Siddharth Singh, MD, MS, of the division of gastroenterology at the University of California, San Diego, and colleagues wrote that limited or uncertain access to nutritional food, which has a prevalence of about 11% nationwide, and factors like lack of social networks or social cohesion and living in unsafe neighborhoods can contribute to adverse health outcomes. READ MORE

PSC-IBD linked with greater growth impairments among children

Features of inflammatory bowel disease differed between children with primary sclerosing cholangitis and those without it, similar to adult patients, according to study results.

“Despite the mild clinical activity of IBD in patients with PSC, lack of symptoms does not always indicate lack of mucosal inflammation,” Amanda Ricciuto, MD, FRCPC, PhD, from the division of gastroenterology, hepatology and nutrition at the Hospital for Sick Children in Toronto, Canada, and colleagues wrote. “Children with PSC-IBD have greater growth impairments compared with children with ulcerative colitis or IBD-unclassified.” READ MORE

Frailty nearly triples mortality odds in IBD

Frailty was independently associated with mortality in a large cohort of patients with inflammatory bowel disease, according to study results.

Ashwin Ananthakrishnan, MD, of the division of gastroenterology at Massachusetts General Hospital, and colleagues wrote that improved treatments and increased global incidence mean that people with IBD are getting older. READ MORE

Curcumin no better than placebo for postoperative Crohn’s recurrence

Oral curcumin was no more effective than placebo for preventing Crohn’s disease recurrence among patients who underwent surgery for Crohn’s, according to study results.

Previous research has shown that curcumin may have some anti-inflammatory properties. Gilles Bommelaer, of Université Clermont Auvergne in France, and colleagues sought to determine its efficacy for the prevention of postoperative Crohn’s recurrence. READ MORE

Q&A: Zeposia may be efficacious oral therapy for UC

Zeposia may be an efficacious new oral therapy option with a favorable risk-benefit profile for patients with ulcerative colitis.

Bristol Myers Squibb recently announced results from the pivotal phase 3 trial, True North, which assessed oral Zeposia (ozanimod, Bristol-Myers Squibb) as an induction and maintenance therapy for adult patients with moderate to severe UC, according to a press release. READ MORE

High-dose vitamin D does not reduce endoscopic recurrence of Crohn’s

For patients who underwent ileocolonic resection with ileocolonic anastomosis, high-dose vitamin D did not reduce the incidence of postoperative endoscopic or clinical recurrence of Crohn’s disease, according to recently published results.

“We are the first to study CD activity during treatment with vitamin D using endoscopy,” Jessica R. de Bruyn, MD, of department of gastroenterology and hepatology from the Amsterdam Inflammatory Bowel Disease Center and Amsterdam Gastroenterology and Metabolism, Amsterdam University Medical Center at University of Amsterdam, and colleagues wrote. “Given all the above, we could not observe any anti-inflammatory effect with this regimen in postoperative CD.” READ MORE

AGA does not recommend probiotics for most GI conditions

In newly issued guidelines, the American Gastroenterological Association did not recommend using probiotics for most digestive conditions.

The society said there was insufficient evidence to make recommendations on the use of probiotics to treat Clostridioides difficile infection, Crohn’s disease, ulcerative colitis or irritable bowel syndrome. If patients with any of these conditions are taking probiotics, the AGA suggested that they stop due to associated costs and lack of evidence concerning potential harm. READ MORE